NCT07059377View on ClinicalTrials.gov

Semaglutide for Smoking Cessation in Patients With Diabetes

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions

Diabetes Mellitus, Type 2Nicotine AddictionTobacco Dependence

Interventions

DRUG

Semaglutide

Starting dose will be 0.25mg once a week for 4 weeks, then titrated up to 0.5mg once a week. For those requiring additional blood sugar control, the dose may be titrated up to the maximum dose of 2mg once a week. All participants will use this medication for up to 26 weeks

DRUG

Nicotine replacement

Nicotine patch plus short-acting NRT gum or lozenge

All Listed Sponsors

lead

Ottawa Heart Institute Research Corporation

OTHER

NCT07059377 - Semaglutide for Smoking Cessation in Patients With Diabetes | Biotech Hunter | Biotech Hunter